Specific power calculations for magnetic resonance imaging (MRI) in monitoring active relapsing-remitting multiple sclerosis (MS): Implications for phase ii therapeutic trials

Multiple Sclerosis

Volumn 2, Issue 6, 1997, Pages 283-290

  Truyen, L ^a,d   Barkhof, F ^a   Tas, M ^a   Van Walderveen, M A A ^a   Frequin, S T F M ^b   Hommes, O R ^b   Nauta, J J P ^c   Polman, C H ^a,d   Valk, J ^a  

^a Dutch MR Centre for MS Research   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Computer simulations; Magnetic resonance imaging; Multiple sclerosis; Trials

Indexed keywords

ADULT; ARTICLE; FEMALE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; RECURRENT DISEASE;

ADULT; CLINICAL TRIALS, PHASE II; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RECURRENCE; RESEARCH DESIGN;

EID: 0030642097     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/135245859700200604     Document Type: Article

References (18)

1. Isaac Cet al.(1988) Multiple sclerosis: a serial study in relapsing patients. Neurology 38: 1511-1515.
2. Truyen Let al.(1991) Longterm follow-up of multiple sclerosis by standardized non-contrast enhanced magnetic resonance imaging. J Neurol Sci 106: 35-40.
3. Harris JOet al.(1991) Serial gadolinium enhanced magnetic resonance imaging scans in patients with early relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 29: 548-555.
4. Barkhof Fet al.(1992) Relapsing-remitting multiple sclerosis: sequential MR imaging vs clinical findings in determining disease activity. AJR 159: 1041-1047.
5. Thompson AJet al.(1991) Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 29: 53-62.
6. Paty DW, Li DKB, the UBC MSMRI Study Group; and the IFNB Multiple Sclerosis Study Group. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo controlled trial. Neurology 43: 662-667.
7. Nauta JJP, Thompson AJ, Barkhof F, Miller DH. (1994) Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: statistical power-calculations of parallel-groups and cross-over design. J Neurol Sci 122: 6-14.
8. Thompson AJet al.(1992) Serial gadolinium-enhanced MRI in relapsing-remitting multiple sclerosis of varying disease duration. Neurology 42: 60-63.
9. Kidd Det al.(1994) Benign form of multiple sclerosis: MRI evidence for less frequent and less inflammatory disease activity. J Neurol Neurosurg Psy 57: 1070-1072.
10. Fillipi Met al.(1995) Brain magnetic resonance and multimodal evoked potentials in benign and secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 58: 31-37.
11. Barkhof F, Hommes OR, Scheltens PH, Valk J. (1991) Quantitative MR changes in gadolinium-DTPA enhancement after treatment with high dose intravenous methylprednisolone. Neurology 41: 1219-1222.
12. Miller DHet al.(1992) High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry 55: 450-453.
13. Miller DH, Barkhof F, Nauta JJP. (1993) Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 116: 1077-1094.
14. McFarland HFet al.(1992) Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 32: 758-766.
15. Poser CMet al.(1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13: 227-231.
16. Kurtzke JF. (1983) Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1444-1452.
17. Miller DHet al.(1996) Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 39: 6-16.
18. Stone LAet al.(1995) Blood brain barrier disruption as measured by contrast enhanced MRI in patients with mild relapsing remitting multiple sclerosis; relationship to course, gender and age. Neurology 45: 1122-1126.